Analysis – Plant-based vaccines challenge big pharma for $3 billion flu market

Two tiny companies are preparing to challenge some of the world’s largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

The use of plants to produce life-saving pharmaceuticals captured global attention when it was revealed that the Ebola drug ZMapp is produced in the leaves of tobacco plants.

Read more